

Resource Summary Report

Generated by [RRID](#) on Aug 11, 2026

[phenoptr](#)

RRID:SCR_026104

Type: Tool

Proper Citation

phenoptr (RRID:SCR_026104)

Resource Information

URL: <https://akoyabio.github.io/phenoptr/index.html>

Proper Citation: phenoptr (RRID:SCR_026104)

Description: Software R package for working with inForm data. Contains functions that make it easier to read and analyze data tables and images created by Akoya Biosciences' inForm software.

Resource Type: source code, software resource

Keywords: read data, analyze data, tables and images, Akoya Biosciences, inForm

Availability: Free, Available for download, Freely available,

Resource Name: phenoptr

Resource ID: SCR_026104

Alternate URLs: <https://github.com/akoyabio/phenoptr>

License: Zlib license

Record Creation Time: 20241127T053252+0000

Record Last Update: 20260810T040923+0000

Ratings and Alerts

No rating or validation information has been found for phenoptr.

No alerts have been found for phenoptr.

Data and Source Information

Usage and Citation Metrics

We found 8 mentions in open access literature.

Listed below are recent publications. The full list is available at [RRID](#) .

Savage G, et al. (2026) Phenotypic Characterization and Prognostic Impact of CD103+ Tissue-Resident Memory T Cells in Diffuse Large B-cell Lymphoma. *Cancer immunology research*, 14(2), 291.

Liao H, et al. (2026) Ectopic CD11c Drives SMAD3-Mediated Aberrant Antigen Presentation and Epithelial-Mesenchymal Transition in Esophageal Squamous Cell Carcinoma. *Cancer communications (London, England)*, 46, 0014.

Jiang X, et al. (2025) Depletion of Effector Regulatory T Cells Associates with Major Response to Induction Dual Immune Checkpoint Blockade. *Cancer discovery*, 15(8), 1569.

Crawford KJ, et al. (2025) Targeting FGFR4 abrogates HNF1A-driven metastasis in pancreatic ductal adenocarcinoma. *Molecular cancer*, 24(1), 208.

Sater S, et al. (2025) Society for Immunotherapy of Cancer: Standards for Reporting of Multiplex Immunohistochemistry/Immunofluorescence Assays (STORMI). *Journal for immunotherapy of cancer*, 13(12).

Daher-Ghanem N, et al. (2025) The responses of HNSCC patients to immunotherapy are shown by two novel co-expression patterns. *NPJ precision oncology*, 9(1), 217.

Koliesnik I, et al. (2025) An IL-12 partial agonist sustains intratumoral lymphocyte activation and detoxifies systemic IL-12 therapy. *Cell reports*, 45(1), 116757.

Campbell MJ, et al. (2024) Multi-platform biomarkers of response to an immune checkpoint inhibitor in the neoadjuvant I-SPY 2 trial for early-stage breast cancer. *Cell reports. Medicine*, 5(11), 101799.